Results 21 to 30 of about 9,514 (200)

Oncogenic Roles and Inhibitors of DNMT1, DNMT3A, and DNMT3B in Acute Myeloid Leukaemia

Biomarker Insights, 2019
Epigenetic alteration has been proposed to give rise to numerous classic hallmarks of cancer. Impaired DNA methylation plays a central role in the onset and progression of several types of malignancies, and DNA methylation is mediated by DNA ...
Kah Keng Wong, Charles H Lawrie, Tina M Green   +2 more
doaj   +1 more source

5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome - a systematic review and meta-analysis

Haematologica, 2010
Hypomethylating agents have recently been shown to improve the outcome of patients with myelodysplastic syndrome. A meta-analysis and systematic review was carried out of randomized controlled trials comparing treatment with hypomethylating agents to ...
Ronit Gurion, Liat Vidal, Anat Gafter-Gvili, Yulia Belnik, Moshe Yeshurun, Pia Raanani, Ofer Shpilberg   +6 more
doaj   +1 more source

An unusual response to 5‐azacitidine by a patient with chronic myelomonocytic leukemia

Clinical Case Reports, 2023
Key Clinical Message Hypomethylating agents may be useful in some but not all cases of myelodysplastic syndromes. In some versions of these conditions, this treatment may yield deleterious results.
Anwarul Islam
doaj   +1 more source

Oral hypomethylating agents: beyond convenience in MDS

Hematology, 2021
AbstractOral hypomethylating agents (HMAs) represent a substantial potential boon for patients with myelodysplastic syndrome (MDS) who have previously required between 5 and 7 visits per month to an infusion clinic to receive therapy. For patients who respond to treatment, ongoing monthly maintenance visits represent a considerable burden to quality of
openaire   +3 more sources

Angioimmunoblastic T‐cell lymphoma after acute myeloid leukemia: Alleged common pathogenesis. A case report and literature review

Clinical Case Reports, 2020
The genomic landscape of AITL is characterized by mutation of epigenetic modifiers. This gene expression pattern resembles myeloid diseases and shows a potential role for hypomethylating agents as possible therapy for AITL.
Isabel Iturrate, Javier Loscertales, Elena Fernández‐Ruiz, Patricia Muñoz, Consuelo López, Luciana del Campo, Cecilia Muñoz, Adrián Alegre   +7 more
doaj   +1 more source

Myelodysplastic syndromes: Where do we stand?

Asian Journal of Oncology, 2016
Myelodysplastic syndromes (MDS) are fairly common hematological disorder of elderly. They are a group of clonal malignant hematopoietic stem cell disorders characterized by dysplastic morphology, variable cytopenia and a variable threat of transformation
Nitin Sood, Bhuvan Chugh, Esha Singhal, Ritesh Sachdev, Shalini Goel, Gajendra Smeeta   +5 more
doaj   +1 more source

Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting

Experimental Hematology & Oncology, 2023
Venetoclax (VEN), the first selective Bcl-2 inhibitor, has shown efficacy and safety both as monotherapy and in combination with other agents in the treatment of newly diagnosed acute myeloid leukemia (AML), while its role in relapsed or refractory (R/R)
Xubo Gong, Yi Zhang, Xin He, Milad Moloudizargari, Teng Yu, Lin Wang, Weiwei Liu, Lan Jin, Huiying Xu, Yang Xu, Zhihua Tao, Wenbin Qian   +11 more
doaj   +1 more source

Novel therapeutic strategies: hypomethylating agents and beyond [PDF]

Hematology, 2012
Abstract The treatment of symptomatic and high-risk myelodysplastic syndrome (MDS) spans several therapeutic goals and options. Key to the successful therapy of these heterogeneous diseases is careful characterization and diagnosis, including clinical, cytogenetic, biological, and molecular evaluation of individual patients.
openaire   +2 more sources

Hypomethylating agent versus venetoclax combination: an electronic health records-based target trial emulation among Asian elderly patients with newly diagnosed acute myeloid leukaemia in Hong Kong

Therapeutic Advances in Hematology
Background: The pivotal trial on venetoclax and hypomethylating agents in unfit elderly acute myeloid leukaemia (AML) has got FDA approval. However, Asian patients were under-represented and showed no survival advantage.
Qiwen Fang, Chi Yeung Fung, Jiaqi Wang, Wing Hei Lai, Raymond S. M. Wong, Bonnie C. S. Kho, June S. M. Lau, Vivien W. M. Mak, Chung Yin Ha, Xue Li, Anskar Yu-Hung Leung   +10 more
doaj   +1 more source

Targeting transcription factors associated with hemoglobinopathies: Lessons from successful interventions and implications for cancer

Molecular Oncology, EarlyView.
This review summarizes the transcription factors, repressive chromatin‐modifying complexes, and epigenetic mechanisms that control fetal hemoglobin repression. Notably, many regulators of γ‐globin silencing also function in transcriptional and epigenetic networks that drive cancer, highlighting opportunities to translate advances in hemoglobinopathy ...
Meigen Yu, Puspa Das, Xing Zhang, Xiaodong Cheng   +3 more
wiley   +1 more source